Pharma giant lands minnow

AstraZeneca, Britain’s second-biggest pharmaceuticals group, has agreed to buy its small US counterpart Omthera for $323m, or $12.70 a share.

AstraZeneca, Britain's second-biggest pharmaceuticals group, has agreed to buy its small US counterpart Omthera for $323m, or $12.70 a share. Omthera specialises in fish-oil-derived heart medicine and its most promising product, Epanova, attacks triglycerides, fats in the blood that cause heart disease. The drug has completed clinical trials but is still awaiting final US regulatory clearance. This purchase is the latest in a series of deals between major drug groups and small, promising pharma or biotech companies.

What the commentators said

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.